JY
JANX icon

Jeff Yass’s Janux Therapeutics JANX Stock Holding History

Jeff Yass’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Sell
113,600
-132,200
-54% -$1.92M ﹤0.01% 6801
2026
Q1 		$3.42M Buy
245,800
+33,300
+16% +$457K ﹤0.01% 5001
2025
Q4 		$2.93M Buy
212,500
+164,900
+346% +$3.88M ﹤0.01% 4905
2025
Q3 		$1.16M Sell
47,600
-15,200
-24% -$370K ﹤0.01% 6996
2025
Q2 		$1.45M Sell
62,800
-48,000
-43% -$1.26M ﹤0.01% 6529
2025
Q1 		$2.99M Buy
110,800
+2,300
+2% +$86.7K ﹤0.01% 4654
2024
Q4 		$5.81M Buy
108,500
+28,500
+36% +$1.51M ﹤0.01% 3379
2024
Q3 		$3.63M Buy
80,000
+25,000
+45% +$1.09M ﹤0.01% 4180
2024
Q2 		$2.3M Sell
55,000
-23,400
-30% -$1.1M ﹤0.01% 4821
2024
Q1 		$2.95M Buy
+78,400
New +$1.71M ﹤0.01% 4553

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Jeff Yass's JANX Position: Q2 2026 in Review

Jeff Yass sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 119,055 shares — an estimated $1.72M sold.

Jeff Yass first reported a position in JANX in Q1 2023 and held it in 10 quarters. The position peaked at $9.96M in Q1 2025. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Jeff Yass reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 119,055 Janux Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Jeff Yass first reported a position in Janux Therapeutics in Q1 2023 and held it in 10 quarters.
  • Jeff Yass's Janux Therapeutics position peaked at $9.96M in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.